111 research outputs found

    Open ventral hernia repair with a composite ventral patch : final results of a multicenter prospective study

    Get PDF
    Background: This study assessed clinical outcomes, including safety and recurrence, from the two-year follow-up of patients who underwent open ventral primary hernia repair with the use of the Parietex (TM) Composite Ventral Patch (PCO-VP). Methods: A prospective single-arm, multicenter study of 126 patients undergoing open ventral hernia repair for umbilical and epigastric hernias with the PCO-VP was performed. Results: One hundred twenty-six subjects (110 with umbilical hernia and 16 with epigastric hernia) with a mean hernia diameter of 1.8cm (0.4-4.0) were treated with PCO-VP. One hundred subjects completed the two-year study. Cumulative hernia recurrence was 3.0% (3/101; 95%CI: 0.0-6.3%) within 24months. Median Numeric Rating Scale pain scores improved from 2 [0-10] at baseline to 0 [0-3] at 1 month (P<0.001) and remained low at 24months 0 [0-6] (P<0.001). 99% (102/103) of the patients were satisfied with their repair at 24months postoperative. Conclusions: The use of PCO-VP to repair primary umbilical and epigastric defects yielded a low recurrence rate, low postoperative and chronic pain, and high satisfaction ratings, confirming that PCO-VP is effective for small ventral hernia repair in the two-year term after implantation. Trial registration: The study was registered publically at clinicaltrials.gov (NCT01848184 registered May 7, 2013)

    EuroBarley:control of leaf diseases in barley across Europe

    Get PDF
    Barley crops are at risk of being attacked by several leaf diseases. Net blotch, brown rust, Rhynchosporium and Ramularia leaf spot are among the most widespread and can cause severe attack and yield losses. Two trial protocols targeting Ramularia and net blotch, respectively, have been tested in several countries in 2021 and 2022. Ramularia trials were situated in Germany, Ireland, Scotland, and Denmark. The net blotch trials were placed in Denmark, Belgium, the UK, Germany, Finland, and France. In the two protocols, 12–13 different fungicide solutions including co-formulations of DMIs, SDHIs, QoIs, and multi-site inhibitors have been tested to compare efficacy and yield responses. Against Ramularia leaf spot, the fungicides were applied at GS 47–51 and against net blotch at GS 37–45. In six trials, the efficacy against Ramularia leaf spot was scored. The results showed a superior control from the co-formulation fluxapyroxad + metyltetraprole (78–100% control), but also solo mefentrifluconazole and the mixtures fluxapyroxad + mefentrifluconazole performed well (average 74–76% control). The mixture fluxapyroxad + metyltetraprole provided the best yield increase followed by Ascra Xpro. Folpet as a solo solution was inferior. Following the net blotch protocol, only three trials developed enough disease to rank the different fungicides; however, in five trials ranking against brown rust was also possible. Most treatments gave very good control of net blotch, and brown rust (&gt; 80% control). The mixture fluxapyroxad + metyltetraprole delivered the best control against all diseases overall. Average yield responses from eight trials showed very similar increases from the tested fungicides.</p

    EuroBarley:control of leaf diseases in barley across Europe

    Get PDF
    Barley crops are at risk of being attacked by several leaf diseases. Net blotch, brown rust, Rhynchosporium and Ramularia leaf spot are among the most widespread and can cause severe attack and yield losses. Two trial protocols targeting Ramularia and net blotch, respectively, have been tested in several countries in 2021 and 2022. Ramularia trials were situated in Germany, Ireland, Scotland, and Denmark. The net blotch trials were placed in Denmark, Belgium, the UK, Germany, Finland, and France. In the two protocols, 12–13 different fungicide solutions including co-formulations of DMIs, SDHIs, QoIs, and multi-site inhibitors have been tested to compare efficacy and yield responses. Against Ramularia leaf spot, the fungicides were applied at GS 47–51 and against net blotch at GS 37–45. In six trials, the efficacy against Ramularia leaf spot was scored. The results showed a superior control from the co-formulation fluxapyroxad + metyltetraprole (78–100% control), but also solo mefentrifluconazole and the mixtures fluxapyroxad + mefentrifluconazole performed well (average 74–76% control). The mixture fluxapyroxad + metyltetraprole provided the best yield increase followed by Ascra Xpro. Folpet as a solo solution was inferior. Following the net blotch protocol, only three trials developed enough disease to rank the different fungicides; however, in five trials ranking against brown rust was also possible. Most treatments gave very good control of net blotch, and brown rust (&gt; 80% control). The mixture fluxapyroxad + metyltetraprole delivered the best control against all diseases overall. Average yield responses from eight trials showed very similar increases from the tested fungicides.</p

    Stellar Population Diagnostics of Elliptical Galaxy Formation

    Full text link
    Major progress has been achieved in recent years in mapping the properties of passively-evolving, early-type galaxies (ETG) from the local universe all the way to redshift ~2. Here, age and metallicity estimates for local cluster and field ETGs are reviewed as based on color-magnitude, color-sigma, and fundamental plane relations, as well as on spectral-line indices diagnostics. The results of applying the same tools at high redshifts are then discussed, and their consistency with the low-redshift results is assessed. Most low- as well as high-redshift (z~1) observations consistently indicate 1) a formation redshift z>~3 for the bulk of stars in cluster ETGs, with their counterparts in low-density environments being on average ~1-2 Gyr younger, i.e., formed at z>~1.5-2, 2) the duration of the major star formation phase anticorrelates with galaxy mass, and the oldest stellar populations are found in the most massive galaxies. With increasing redshift there is evidence for a decrease in the number density of ETGs, especially of the less massive ones, whereas existing data appear to suggest that most of the most-massive ETGs were already fully assembled at z~1. Beyond this redshift, the space density of ETGs starts dropping significantly, and as ETGs disappear, a population of massive, strongly clustered, starburst galaxies progressively becomes more and more prominent, which makes them the likely progenitors to ETGs.Comment: To appear on Annual Review of Astronomy & Astrophysics, Vol. 44 (2006). 46 pages with 16 figures. Replaced version includes updated references, few typos less, and replaces Fig. 11 and Fig. 16 which had been skrewed u

    Video-supported Analysis of Beggiatoa Filament Growth, Breakage, and Movement

    Get PDF
    A marine Beggiatoa sp. was cultured in semi-solid agar with opposing oxygen-sulfide gradients. Growth pattern, breakage of filaments for multiplication, and movement directions of Beggiatoa filaments in the transparent agar were investigated by time-lapse video recording. The initial doubling time of cells was 15.7 ± 1.3 h (mean ± SD) at room temperature. Filaments grew up to an average length of 1.7 ± 0.2 mm, but filaments of up to approximately 6 mm were also present. First breakages of filaments occurred approximately 19 h after inoculation, and time-lapse movies illustrated that a parent filament could break into several daughter filaments within a few hours. In >20% of the cases, filament breakage occurred at the tip of a former loop. As filament breakage is accomplished by the presence of sacrificial cells, loop formation and the presence of sacrificial cells must coincide. We hypothesize that sacrificial cells enhance the chance of loop formation by interrupting the communication between two parts of one filament. With communication interrupted, these two parts of one filament can randomly move toward each other forming the tip of a loop at the sacrificial cell

    Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women

    Get PDF
    The P2X7 receptor gene (P2RX7) is highly polymorphic with five previously described loss-of-function (LOF) single-nucleotide polymorphisms (SNP; c.151+1G>T, c.946G>A, c.1096C>G, c.1513A>C and c.1729T>A) and one gain-of-function SNP (c.489C>T). The purpose of this study was to determine whether the functional P2RX7 SNPs are associated with lumbar spine (LS) bone mineral density (BMD), a key determinant of vertebral fracture risk, in post-menopausal women. We genotyped 506 post-menopausal women from the Aberdeen Prospective Osteoporosis Screening Study (APOSS) for the above SNPs. Lumbar spine BMD was measured at baseline and at 6–7 year follow-up. P2RX7 genotyping was performed by homogeneous mass extension. We found association of c.946A (p.Arg307Gln) with lower LS-BMD at baseline (P=0.004, β=−0.12) and follow-up (P=0.002, β=−0.13). Further analysis showed that a combined group of subjects who had LOF SNPs (n=48) had nearly ninefold greater annualised percent change in LS-BMD than subjects who were wild type at the six SNP positions (n=84; rate of loss=−0.94%/year and −0.11%/year, respectively, P=0.0005, unpaired t-test). This is the first report that describes association of the c.946A (p.Arg307Gln) LOF SNP with low LS-BMD, and that other LOF SNPs, which result in reduced or no function of the P2X7 receptor, may contribute to accelerated bone loss. Certain polymorphic variants of P2RX7 may identify women at greater risk of developing osteoporosis

    Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Efficacy studies indicate anti-depressive effects of at least some second generation antipsychotics (SGAs). The Bergen Psychosis Project (BPP) is a 24-month, pragmatic, industry-independent, randomized, head-to-head comparison of olanzapine, quetiapine, risperidone and ziprasidone in patients acutely admitted with psychosis. The aim of the study is to investigate whether differential anti-depressive effectiveness exists among SGAs in a clinically relevant sample of patients acutely admitted with psychosis.</p> <p>Methods</p> <p>Adult patients acutely admitted to an emergency ward for psychosis were randomized to olanzapine, quetiapine, risperidone or ziprasidone and followed for up to 2 years. Participants were assessed repeatedly using the Positive and Negative Syndrome Scale - Depression factor (PANSS-D) and the Calgary Depression Scale for Schizophrenia (CDSS).</p> <p>Results</p> <p>A total of 226 patients were included. A significant time-effect showing a steady decline in depressive symptoms in all medication groups was demonstrated. There were no substantial differences among the SGAs in reducing the PANSS-D score or the CDSS sum score. Separate analyses of groups with CDSS sum scores > 6 or ≤6, respectively, reflecting degree of depressive morbidity, revealed essentially identical results to the primary analyses. There was a high correlation between the PANSS-D and the CDSS sum score (r = 0.77; p < 0.01).</p> <p>Conclusions</p> <p>There was no substantial difference in anti-depressive effectiveness among olanzapine, quetiapine, risperidone or ziprasidone in this clinically relevant sample of patients acutely admitted to hospital for symptoms of psychosis. Based on our findings we can make no recommendations concerning choice of any particular SGA for targeting symptoms of depression in a patient acutely admitted with psychosis.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov ID; URL: <url>http://www.clinicaltrials.gov/</url>: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00932529">NCT00932529</a></p
    corecore